|
US5700913A
(en)
|
1982-12-15 |
1997-12-23 |
Ajinomoto Co., Inc. |
Unglycosylated human interleukin-2 polypeptides
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
PT83761B
(pt)
|
1985-11-19 |
1989-06-30 |
Schering Biotech Corp |
Metodo para a producao de interleuquina-4 de mamifero
|
|
US6028186A
(en)
|
1991-06-10 |
2000-02-22 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of cytokines
|
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
|
US7008624B1
(en)
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
ZA967182B
(en)
|
1995-08-24 |
1998-05-25 |
Magainin Pharma |
Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
|
|
IL130238A0
(en)
|
1999-06-01 |
2000-06-01 |
Peptor Ltd |
Conformationally constrained backbone cyclized interleukin-6 antagonists
|
|
EP0918858A1
(en)
|
1996-05-10 |
1999-06-02 |
Biogen, Inc. |
Common gamma chain blocking agents
|
|
US6127387A
(en)
|
1996-12-10 |
2000-10-03 |
Thomas Jefferson University |
Use of CD4-binding small molecules to inhibit immune responses
|
|
ATE375363T1
(de)
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
|
US6861227B2
(en)
|
1998-03-19 |
2005-03-01 |
Human Genome Sciences, Inc. |
Antibodies to cytokine receptor common gamma chain like
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EP0972780A1
(en)
|
1998-05-18 |
2000-01-19 |
Applied Research Systems ARS Holding N.V. |
Il-6 antagonist peptides
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
|
BR0110779A
(pt)
|
2000-05-12 |
2005-01-11 |
Beth Israel Hospital |
Composições e métodos para adquirir supressão imunológica
|
|
ATE427318T1
(de)
|
2000-09-14 |
2009-04-15 |
Beth Israel Hospital |
Modulierung von il-2 und il-15 vermittelten t zellantworten
|
|
AU2002246746B2
(en)
|
2000-10-18 |
2007-05-31 |
Kirin-Amgen, Inc. |
Methods for treating rheumatoid arthritis using il-17 antagonists
|
|
WO2003004098A1
(en)
|
2001-07-06 |
2003-01-16 |
Sucampo Ag |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
|
CA2465268A1
(en)
|
2001-10-24 |
2003-05-01 |
National Jewish Medical And Research Center |
Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
|
|
DK1451322T3
(da)
|
2001-11-05 |
2010-02-01 |
Zymogenetics Inc |
Il-21-antagonister
|
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
WO2003087320A2
(en)
|
2002-04-09 |
2003-10-23 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonists of il-21 and modulation of il-21-mediated t cell responses
|
|
AU2003243189B2
(en)
|
2002-05-01 |
2008-01-24 |
Regeneron Pharmaceuticals, Inc. |
Methods of using cytokine antagonists to treat HIV infection and AIDS
|
|
MXPA04012116A
(es)
|
2002-06-07 |
2005-04-19 |
Zymogenetics Inc |
Uso del il-21 en cancer y otras aplicaciones terapeuticas.
|
|
CA2490804C
(en)
|
2002-06-28 |
2016-12-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
|
WO2004003156A2
(en)
|
2002-07-01 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Il-21 as a regulator of immunoglobin production
|
|
CN1688340A
(zh)
|
2002-07-15 |
2005-10-26 |
韦思公司 |
调节t辅助(th)细胞发育和功能的方法和组合物
|
|
US20060236411A1
(en)
|
2002-10-14 |
2006-10-19 |
Ingeborg Dreher |
Antagonists il-15
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
KR20060015482A
(ko)
|
2003-03-21 |
2006-02-17 |
와이어쓰 |
인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
|
|
ATE473239T1
(de)
|
2003-05-14 |
2010-07-15 |
Bayer Pharmaceuticals Corp |
Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren
|
|
WO2004112703A2
(en)
|
2003-06-19 |
2004-12-29 |
Centocor, Inc. |
Interleukin-21 analogs
|
|
DK1648931T3
(da)
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7785580B2
(en)
|
2003-08-29 |
2010-08-31 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
WO2005067956A2
(en)
|
2004-01-15 |
2005-07-28 |
Novo Nordisk A/S |
Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
|
|
JP5064212B2
(ja)
|
2004-05-05 |
2012-10-31 |
ヴァロリザーシヨン−ルシェルシュ，ソシエテ・アン・コマンディット |
インターロイキン−１受容体アンタゴニスト、組成物、及び治療方法
|
|
US20060024268A1
(en)
|
2004-05-19 |
2006-02-02 |
Wyeth |
Modulation of immunoglobulin production and atopic disorders
|
|
CA2574848A1
(en)
|
2004-08-05 |
2006-12-21 |
Wyeth |
Antagonizing interleukin-21 receptor activity
|
|
CU23472A1
(es)
|
2004-09-17 |
2009-12-17 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la interleucina-15
|
|
WO2006105538A2
(en)
|
2005-03-31 |
2006-10-05 |
Centocor, Inc. |
Methods and compositions for treating il-21 related pathologies
|
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US8512946B2
(en)
|
2005-08-10 |
2013-08-20 |
Northwestern University |
Composite particles
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
AU2006340750B2
(en)
|
2005-11-28 |
2013-03-07 |
Zymogenetics, Inc. |
IL-21 antagonists
|
|
EP2066689A4
(en)
|
2006-09-07 |
2010-04-28 |
Univ South Florida |
HYD1-PEPTIDE AS ANTICREMENT
|
|
AU2007310777A1
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
IL-21 variants
|
|
CA2671665A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo-Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
US7910123B2
(en)
|
2007-09-05 |
2011-03-22 |
Warsaw Orthopedic |
Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
|
|
WO2009100035A2
(en)
|
2008-02-01 |
2009-08-13 |
Wyeth |
Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
|
|
WO2009108341A1
(en)
|
2008-02-28 |
2009-09-03 |
Argos Therapeutics, Inc. |
Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
|
|
WO2009132821A1
(en)
|
2008-04-28 |
2009-11-05 |
Giuliani International Limited |
Interleukin (il-21) binding proteins and methods of making and using same
|
|
EP2303353B1
(en)
|
2008-06-12 |
2018-01-10 |
Ramot at Tel-Aviv University Ltd. |
Drug-eluting medical devices
|
|
WO2010011313A2
(en)
|
2008-07-23 |
2010-01-28 |
President And Fellows Of Harvard College |
Ligation of stapled polypeptides
|
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
|
NZ592943A
(en)
|
2008-11-17 |
2012-09-28 |
Uinv Kobenhavns |
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
|
|
WO2010076339A1
(en)
|
2009-01-05 |
2010-07-08 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
|
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
|
EP2406282A1
(en)
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
JP2012532929A
(ja)
*
|
2009-07-13 |
2012-12-20 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二機能性のステープリングされたポリペプチドおよびそれらの使用
|
|
AU2010329805B2
(en)
|
2009-12-11 |
2016-07-14 |
Proyecto De Biomedicina Cima S.L. |
New conjugates and compositions for immunotherapy and anti-tumoral treatment
|
|
CN102858367B
(zh)
|
2010-02-26 |
2014-12-17 |
国立大学法人长崎大学 |
抗原或药物递送复合物
|
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
US8822642B2
(en)
|
2010-06-09 |
2014-09-02 |
Zymogenetics, Inc. |
Dimeric fusion proteins and related compositions and methods
|
|
US9084761B2
(en)
|
2010-07-09 |
2015-07-21 |
The Regents Of The University Of California |
Use of interleukin-15 to treat cardiovascular diseases
|
|
EP2596023A4
(en)
|
2010-07-20 |
2014-03-05 |
Beth Israel Hospital |
COMPOSITIONS AND METHODS FOR IL-6 AND IL-21 ANTAGONISTS
|
|
HRP20200470T1
(hr)
|
2011-01-18 |
2020-10-02 |
Bioniz, Llc |
Pripravci za modulaciju aktivnosti gama-c-citokina
|
|
US20240043475A1
(en)
|
2011-01-18 |
2024-02-08 |
Bioniz, Llc |
Peptide conjugates
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
US9959384B2
(en)
|
2013-12-10 |
2018-05-01 |
Bioniz, Llc |
Methods of developing selective peptide antagonists
|
|
EP3350205A1
(en)
|
2015-09-16 |
2018-07-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
|
|
CN119684428A
(zh)
|
2015-10-09 |
2025-03-25 |
比奥尼斯治疗公司 |
调节γC-细胞因子活性
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
WO2018187499A1
(en)
|
2017-04-07 |
2018-10-11 |
Bioniz, Llc |
Stable modulators of gamma-c-cytokine activity
|
|
EP3976182A4
(en)
|
2019-05-03 |
2023-01-18 |
Bioniz, LLC |
MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS
|
|
EP4172175A4
(en)
|
2020-06-24 |
2024-07-24 |
Bioniz Therapeutics, Inc. |
Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders
|